Drug Price Trends for LEVETIRACETAM

Average Pharmacy Cost for LEVETIRACETAM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
LEVETIRACETAM 1,000 MG TABLET	82009-0124-60	0.16582	EACH	2025-05-21
LEVETIRACETAM 750 MG TABLET	82009-0123-05	0.12026	EACH	2025-05-21
LEVETIRACETAM 500 MG TABLET	82009-0122-05	0.08149	EACH	2025-05-21
LEVETIRACETAM 250 MG TABLET	82009-0121-05	0.06134	EACH	2025-05-21
LEVETIRACETAM 1,000 MG TABLET	72205-0097-60	0.16582	EACH	2025-05-21
LEVETIRACETAM 750 MG TABLET	72205-0096-92	0.12026	EACH	2025-05-21
LEVETIRACETAM 500 MG TABLET	72205-0095-92	0.08149	EACH	2025-05-21

Best Wholesale Price for LEVETIRACETAM

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
LEVETIRACETAM 100MG/ML INJ	Sagent Pharmaceuticals	25021-0780-05	10X5ML	3.52			2024-05-01 - 2029-04-30	FSS
LEVETIRACETAM 1500MG/100ML 0.82% NACL INJECT	Mylan Institutional LLC	67457-0266-10	10X100ML	132.91			2023-09-29 - 2028-09-28	Big4
LEVETIRACETAM 500MG/100ML 0.82% NACL INJECTIO	Mylan Institutional LLC	67457-0255-10	10X100ML	126.63			2024-01-01 - 2028-09-28	FSS
LEVETIRACETAM 1500MG/100ML 0.82% NACL INJECT	Mylan Institutional LLC	67457-0266-10	10X100ML	132.91			2023-09-29 - 2028-09-28	FSS
LEVETIRACETAM 1000MG/100ML 0.82% NACL INJECT	Mylan Institutional LLC	67457-0265-10	10X100ML	95.58			2023-09-29 - 2028-09-28	Big4
LEVETIRACETAM 1500MG/100ML 0.82% NACL INJECT	Mylan Institutional LLC	67457-0266-10	10X100ML	155.78			2023-10-12 - 2028-09-28	FSS
LEVETIRACETAM 1000MG/100ML 0.82% NACL INJECT	Mylan Institutional LLC	67457-0265-10	10X100ML	95.58			2023-09-29 - 2028-09-28	FSS

Market Analysis and Price Projections for Levetiracetam

Introduction to Levetiracetam

Levetiracetam, commonly known by the brand name Keppra, is a widely used antiepileptic medication. It is prescribed for the treatment of various types of seizures, including partial onset seizures, myoclonic seizures, and tonic-clonic seizures. The drug has gained significant traction due to its efficacy, tolerability, and ease of use.

Global Market Size and Growth

The global levetiracetam market is experiencing substantial growth, driven by several key factors. As of 2023, the global levetiracetam market size was valued at a significant figure, with a projected compound annual growth rate (CAGR) from 2024 to 2031[1].

Market Drivers

1. Increasing Prevalence of Epilepsy

   • The rising prevalence of epilepsy and seizure disorders is a primary driver of the levetiracetam market. As more individuals are diagnosed and seek treatment, the demand for effective antiepileptic medications like levetiracetam continues to grow[4].

2. Innovation in Pharmaceutical Formulations

   • Extended-release versions and generic alternatives of levetiracetam enhance patient convenience and affordability, widening the market reach. These innovations are crucial in expanding the market[4].

3. Pediatric and Off-Label Use

   • The approval of levetiracetam for use in children has expanded its patient base. Additionally, the off-label use of levetiracetam in conditions like neuropathic pain and mood disorders is gaining recognition, further fueling market demand[4].

Segment Analysis

1. Type Segmentation

   • The levetiracetam market is segmented based on type, including immediate-release tablets, extended-release tablets, and oral solutions. The tablet segment, particularly the immediate-release tablets, accounted for a noticeable share of the global market in 2023 and is projected to experience significant growth in the near future[1].

2. Application Segmentation

   • The market is also segmented based on application, with the myoclonic treatment segment expected to expand at a significant CAGR throughout the forecast period[1].

3. Distribution Channel Segmentation

   • The distribution channels include pharmacies, hospitals, and online retailers. The ease of availability through these channels contributes to the market growth[1].

Regional Analysis

The levetiracetam market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Each region provides revenue share, current trends, and key contributing countries. This regional analysis helps in understanding the market dynamics and growth prospects in different geographical areas[1].

Price Projections

The prices of levetiracetam vary based on the dosage form, quantity, and pharmacy.

• Oral Tablets:

  • For a supply of 120 tablets of 500 mg levetiracetam oral tablets, the cost can range from $17.97 to $119.57, depending on the pharmacy and availability[2].

• Extended-Release Tablets:

  • The cost for 30 tablets of 500 mg extended-release levetiracetam can range from $22.11 to $79.14[2].

• Oral Solution:

  • The cost for 473 milliliters of levetiracetam oral solution can range from $25.92 to $93.15[2].

Cost-Effectiveness and Clinical Efficacy

While levetiracetam is widely prescribed due to its ease of use and tolerability, cost-utility analyses have shown mixed results. A study published in The Lancet found that levetiracetam was not cost-effective compared to lamotrigine at certain cost-effectiveness thresholds. However, it remains a valuable treatment option due to its clinical efficacy and patient compliance[3].

Competitive Landscape

Key companies such as UCB Pharma and Eisai Inc. are focusing on strategy building to strengthen their product portfolios and expand their business in the global market. These companies are investing in research and development to enhance the formulations and delivery methods of levetiracetam, further driving market growth[1].

Manufacturing and Market Trends

The manufacturing of levetiracetam involves detailed unit operations, raw material requirements, and specific machinery and technology. The report by IMARC Group provides a comprehensive roadmap for setting up a levetiracetam manufacturing plant, including project economics, capital investments, and expected ROI[4].

Future Market Opportunities

The epilepsy drugs market, which includes levetiracetam, is projected to reach USD 11.7 billion by 2030, growing at a CAGR of 3.8% from 2023 to 2030. This growth is driven by increasing awareness of epilepsy, expanding applications of antiepileptic medications, and advancements in pharmaceutical formulations[5].

Key Takeaways

• The global levetiracetam market is experiencing significant growth driven by the increasing prevalence of epilepsy and innovations in pharmaceutical formulations.
• The tablet segment, particularly immediate-release tablets, dominates the market and is expected to grow significantly.
• Regional analysis shows diverse market dynamics across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
• Price variations exist based on dosage form, quantity, and pharmacy.
• Levetiracetam's cost-effectiveness is mixed compared to other antiepileptic drugs but remains a valuable treatment option.
• Key companies are focusing on strengthening their product portfolios and expanding their market presence.

FAQs

1. What is the current market size of the global levetiracetam market?

• As of 2023, the global levetiracetam market size was valued at a significant figure, though the exact amount is not disclosed in the available sources.

2. What is the projected CAGR for the levetiracetam market from 2024 to 2031?

• The compound annual growth rate (CAGR) for the levetiracetam market from 2024 to 2031 is expected to be significant, though the exact percentage is not specified in the available sources.

3. Which segment of the levetiracetam market is expected to grow significantly?

• The myoclonic treatment segment is expected to expand at a significant CAGR throughout the forecast period.

4. How does the cost of levetiracetam vary?

• The cost of levetiracetam varies based on the dosage form, quantity, and pharmacy. For example, 120 tablets of 500 mg levetiracetam oral tablets can cost between $17.97 and $119.57.

5. Is levetiracetam cost-effective compared to other antiepileptic drugs?

• According to a study published in The Lancet, levetiracetam was not found to be cost-effective compared to lamotrigine at certain cost-effectiveness thresholds, though it remains a valuable treatment option due to its clinical efficacy and patient compliance.

Cited Sources:

1. Cognitive Market Research: Levetiracetam Market Report 2024 (Global Edition)
2. Drugs.com: Levetiracetam Prices, Coupons, Copay Cards & Patient Assistance
3. The Lancet: The SANAD II study of the effectiveness and cost ...
4. IMARC Group: Levetiracetam (Keppra) Manufacturing Plant Project Report 2024
5. GlobeNewswire: Epilepsy Drugs Market projected to reach USD 11.7 Billion by 2030

Last updated: 2024-12-30